---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-064456"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:19:02.300982+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics announces DRP licensing and lab services deal with EU biotech

## Summary
- Non-exclusive global license to selected DRP algorithms in breast cancer granted to an undisclosed EU-based biotech company.
- Allarity will provide advanced transcriptome analysis services from its Denmark lab; purchase commitments secured for next year.
- Company states the agreement is not expected to have a significant impact on its financial outlook.
- CEO Thomas Jensen says deal validates DRP platform and offsets internal operating costs.

## SEC filing metadata
- accession: 0001213900-25-064456
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390025064456/0001213900-25-064456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390025064456/ea0249097-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-064456
- JSON: https://secwatch.observer/filing/0001213900-25-064456.json
- Plain text: https://secwatch.observer/filing/0001213900-25-064456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.